If today's cancers are better characterized and treated, the therapeutic treatment resistance and relapse remain highly problematic. A powerful approach combining proteomics offers an original concept that cancers are derived from the massive and inappropriate activation of specific genes in other tissues, three teams of Grenoble research, involving researchers from Inserm, CEA, CNRS and Université Joseph Fourier - Grenoble I and doctors CHU Grenoble, have made a major discovery in the field of treatment of aggressive lymphoid cancers.